<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495131</url>
  </required_header>
  <id_info>
    <org_study_id>200705080M</org_study_id>
    <nct_id>NCT00495131</nct_id>
  </id_info>
  <brief_title>Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients</brief_title>
  <official_title>Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is prevalent in the world, affecting 3% of the
      world's population. The current standard of therapy is pegylated interferon and ribavirin,
      reaching 54-63% of successful rates. In patients with HCV genotype 1 infection, a 48 week
      course of combination therapy has achieved a higher successful rate that a 24 weeks course of
      therapy. However, several studies in Taiwan have shown that a 24 week course of therapy has
      comparable or even better response to a 48 week course of therapy in Western countries.
      Therefore, whether a 48 week course of therapy can achieve a higher response to a 24 week
      course of therapy in Taiwanese patients with genotype 1 HCV infection remains unclear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination therapy with interferon alfa (IFN-α) plus ribavirin for 24 to 48 weeks produces
      sustained virologic response (SVR) rate in approximately 31-47% of treatment naïve patients
      with chronic hepatitis C.(1-5) Patients with genotype 1 virus infection are less likely to
      have SVR that those with other genotypes infection, and therefore, patients infected with
      hepatitis C virus (HCV) genotype 1 should receive treatment for 48 weeks.(6) Recently,
      combination therapy with pegylated interferon alfa (pegylated IFN-α) plus ribavirin produces
      higher SVR rates (54-56%) than that with IFN-α plus ribavirin.(7,8) Furthermore, a large
      trial assessing the effect and duration of pegylated IFN-α plus ribavirin showed that the
      overall SVR rate was 63%. Among patients with genotype 1 HCV infection, standard dose
      ribavirin (1000 to 1200 mg per day) and 48 weeks of treatment were significantly more
      effective than low dose ribavirin (800 mg per day) or 24 weeks of treatment.(9) The SVR rate
      was 51% for genotype 1 patients receiving pegylated IFN-α plus standard dose ribavirin for 48
      weeks, whereas only 29% and 41% for those receiving pegylated IFN-α plus low dose ribavirin
      and standard dose ribavirin for 24 weeks, respectively. Based on these lines of evidence, 48
      weeks of therapy with pegylated IFN-α (pegylated IFN-α 2a 180 μg or pegylated IFN-α 2b 1.5 μg
      per kilogram body weight weekly) plus ribavirin (1000 to 1200 mg per day) is recommended to
      treat patients with HCV genotype 1 infection.(10) In Taiwan, a multicenter study showed that
      a 6 month course treatment with pegylated IFN-α plus standard dose ribavirin had a comparable
      SVR rate to that with IFN-α plus standard dose ribavirin (67.1% versus 63.6%) in patients
      with chronic hepatitis C. Subgroup analysis showed that treatment with pegylated IFN-α plus
      standard dose ribavirin had a significantly higher SVR rate to that with IFN-α plus standard
      dose ribavirin (65.8% versus 41.0%) in patients with genotype 1 HCV infection.(11) Recently,
      a pilot study comparing 24 and 48 weeks of pegylated IFN-α plus standard dose ribavirin in
      patients with genotype 1 HCV infection showed that 48 weeks of treatment is more efficacious
      that 24 weeks of treatment (SVR rate: 80.0% versus 48.9%).(12) However, much difference of
      SVR rates occurred in these two studies, making optimal therapy in Taiwanese patients
      infected with genotype 1 HCV difficult to be determined. In the study, we aim to investigate
      in a large cohort whether 48 weeks treatment with pegylated IFN-α plus standard dose
      ribavirin is more efficacious than 24 weeks treatment in patients with genotype 1 HCV
      infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Biochemical Response</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Withdrawal Rate</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic Response</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Peginterfron and ribavirin (24 weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon and ribavirin (48 weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a plus ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
    <arm_group_label>Peginterfron and ribavirin (24 weeks)</arm_group_label>
    <other_name>Pegasys plus Robatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a plus ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
    <arm_group_label>Peginterferon and ribavirin (48 weeks)</arm_group_label>
    <other_name>Pegasys plus Robatrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naïve

          -  Age 18 and older than 18 years old

          -  Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months

          -  Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche
             Molecular Systems, Pleasanton, CA) with dynamic range 600~&lt;500,000 IU/ml

          -  HCV genotype 1 (Inno-LiPA HCV II, Innogenetics, Ghent, Belgium)

          -  Serum alanine aminotransferase levels above the upper limit of normal with 6 months of
             enrollment

          -  A liver biopsy consistent with the diagnosis of chronic hepatitis C

        Exclusion Criteria:

          -  Anemia (hemoglobin &lt; 13 gram per deciliter for men and &lt; 12 gram per deciliter for
             women)

          -  Neutropenia (neutrophil count &lt;1,500 per cubic milliliter)

          -  Thrombocytopenia (platelet &lt;90,000 per cubic milliliter)

          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Chronic alcohol abuse (daily consumption &gt; 20 gram per day)

          -  Decompensated liver disease (Child-Pugh class B or C)

          -  Serum creatinine level more than 1.5 times the upper limit of normal

          -  Autoimmune liver disease

          -  Neoplastic disease

          -  An organ transplant

          -  Immunosuppressive therapy

          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,
             psychiatric diseases, neurological diseases, diabetes mellitus

          -  Evidence of drug abuse

          -  Unwilling to have contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ding-Shinn Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-Yang Lai, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pei-Jer Chen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chun-Jen Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-Jer Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hosptial, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Lin Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ren-Ai Branch, Taipei City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Chao Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ching-Sheng Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Shun Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ren-Ai Branch, Taipei Municipal Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485-92.</citation>
    <PMID>9819446</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998 Oct 31;352(9138):1426-32.</citation>
    <PMID>9807989</PMID>
  </reference>
  <reference>
    <citation>Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996 Nov;111(5):1307-12.</citation>
    <PMID>8898645</PMID>
  </reference>
  <reference>
    <citation>Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol. 1995;23 Suppl 2:8-12.</citation>
    <PMID>8720287</PMID>
  </reference>
  <reference>
    <citation>Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998 Jan 10;351(9096):83-7.</citation>
    <PMID>9439491</PMID>
  </reference>
  <reference>
    <citation>EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol. 1999 May;30(5):956-61. Review.</citation>
    <PMID>10365827</PMID>
  </reference>
  <reference>
    <citation>Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.</citation>
    <PMID>11583749</PMID>
  </reference>
  <reference>
    <citation>Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.</citation>
    <PMID>12324553</PMID>
  </reference>
  <reference>
    <citation>Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346-55.</citation>
    <PMID>14996676</PMID>
  </reference>
  <reference>
    <citation>National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology. 2002 Nov;36(5 Suppl 1):S3-20. Review.</citation>
    <PMID>12407572</PMID>
  </reference>
  <reference>
    <citation>Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. 2005 May;12(3):283-91.</citation>
    <PMID>15850469</PMID>
  </reference>
  <reference>
    <citation>Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int. 2006 Feb;26(1):73-81.</citation>
    <PMID>16420512</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <results_first_submitted>December 21, 2008</results_first_submitted>
  <results_first_submitted_qc>July 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2009</results_first_posted>
  <last_update_submitted>September 7, 2009</last_update_submitted>
  <last_update_submitted_qc>September 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jia-Horng Kao</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Interferon</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 2006 June to September Location: academic centers</recruitment_details>
      <pre_assignment_details>No wash out period in the study; all were treatment-naive All the patients who were eligible in the study were assigned to either groups without exclusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon and Ribavirin (24 Weeks)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Peginterferon and Ribavirin (48 Weeks)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon and Ribavirin (24 Weeks)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Peginterferon and Ribavirin (48 Weeks)</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="308"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="10"/>
                    <measurement group_id="B2" value="53" spread="11"/>
                    <measurement group_id="B3" value="53" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Withdrawal Rate</title>
        <description>Treatment-related withdrawal rate: patients who prematurely discontinued treatment due to treatment-related adverse events</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Ribavirin (24 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon and Ribavirin (48 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Withdrawal Rate</title>
          <description>Treatment-related withdrawal rate: patients who prematurely discontinued treatment due to treatment-related adverse events</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response</title>
        <description>Undetectable HCV RNA 6 months off therapy</description>
        <time_frame>18 months</time_frame>
        <population>Intention-to-treat (ITT) analysis by last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Ribavirin (24 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon and Ribavirin (48 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response</title>
          <description>Undetectable HCV RNA 6 months off therapy</description>
          <population>Intention-to-treat (ITT) analysis by last observation carried forward</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between 2 groups SVR estimation: 24 weeks (60%), 48 weeks (75%) alfa erros: 0.05, power: 0.80</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sustained Biochemical Response</title>
        <description>Sustained biochemical response (SBR): alanine aminotransferase (ALT) normalization</description>
        <time_frame>18 months</time_frame>
        <population>Patients with end of follow-up alanine aminotransferase (ALT) levels</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Ribavirin (24 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon and Ribavirin (48 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Biochemical Response</title>
          <description>Sustained biochemical response (SBR): alanine aminotransferase (ALT) normalization</description>
          <population>Patients with end of follow-up alanine aminotransferase (ALT) levels</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histologic Response</title>
        <description>Histologic response: improvement of at least 2 grade of scores by Ishak liver histologic classification by end of follow up liver biopsy to baseline liver biopsy</description>
        <time_frame>18 months</time_frame>
        <population>Data included for analysis only for patients with paired liver biopsies.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Ribavirin (24 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon and Ribavirin (48 Weeks)</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Histologic Response</title>
          <description>Histologic response: improvement of at least 2 grade of scores by Ishak liver histologic classification by end of follow up liver biopsy to baseline liver biopsy</description>
          <population>Data included for analysis only for patients with paired liver biopsies.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chen-Hua Liu, MD</name_or_title>
      <organization>National Taiwan University Hospital</organization>
      <phone>886223123456 ext 63572</phone>
      <email>jacque_liu@mail2000.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

